• 1
    Lo CM, Fung JTK, Lau GKK, Liu CL, Cheung ST, Lai CL, Fan ST, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37:3643.
  • 2
    Chan HLY, Chui AKK, Lau WY, Chan FKL, Wong ML, Tse CH, Rao ARN, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68:182187.
  • 3
    Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, Shaw J, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30:715721.
  • 4
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 22:424432.
  • 5
    Lai CL, Rosmawati M, Lao J, Vlierberghe HV, Anderson FH, Thomas N, Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123:18311838.
  • 6
    Chan HLY, Wong ML, Leung NWY, Hui AY, Hung LCT, Chan FKL, Sung JJY. Pegylated interferon has additional antiviral effect on lamivudine in the treatment of chronic hepatitis B. Hepatology 2002; 36:624A.
  • 7
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhauou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847.